Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin alfa weekly versus every-2-weeks in pediatric chronic kidney disease anemia
2008-003418-88Phase 3Completed
- Sponsor
- Amgen
- Start
- Oct 2008
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of darbepoetin alfa in anemia of renal disease and chronic kidney disease (CKD) (2 arms), sponsored by Amgen. Primary endpoint: Primary efficacy endpoint. Started Oct 2008; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anemia of renal diseasechronic kidney disease (CKD)
Beyond the preview
Go deeper on 2008-003418-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003418-88.